{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:42Z","timestamp":1790949162155,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary biliary cholangitis (PBC) is a chronic intrahepatic cholestatic autoimmune liver disease characterized by inflammatory injury of small and medium-sized bile ducts in the liver. The pathogenesis of PBC has yet to be entirely understood. CD47\/signal-regulatory protein alpha (SIRP\u03b1) is closely related to developing autoimmune diseases by promoting inflammatory response. However, the effect of CD47\/SIRP\u03b1 on inflammatory response in PBC patients is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We investigated the expression of CD47\/SIRP\u03b1 and the effect of inflammatory cytokines on the CD47 expression, analyzed potential autoantibodies against CD47 and the effect of anti-CD47 antibody on the inflammatory response in PBC, provided laboratory basis for the study of the pathogenesis and targets for non-invasive diagnosis and treatment on PBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The expression levels of CD47 and SIRP\u03b1 on peripheral blood mononuclear cells (PBMC) were measured in 14 patients with PBC (the PBC group) and 13 healthy subjects (the Control group) by flow cytometry (FCM). The PBMC derived from healthy subjects were stimulated with healthy subjects\u2019 serum, PBC patients\u2019 serum, IFN-\u03b1 or TNF-\u03b1, and the CD47 expression level on CD14<jats:sup>+<\/jats:sup> monocytes was detected by FCM. The level of serum anti-CD47 antibody or IFN-\u03b1 in PBC patients and healthy subjects was analyzed by ELISA. FCM was used to examine the TNF-\u03b1 expression level in CD14<jats:sup>+<\/jats:sup> monocytes of healthy subjects stimulated with isotype control antibody, anti-CD47 antibody, LPS or LPS combined with CD47 antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The CD47 expression level on the CD14<jats:sup>+<\/jats:sup> monocytes in PBC patients was statistically higher than that in the Control group (<jats:italic>P<\/jats:italic>&amp;lt;0.01). Compared with the Control group (PBMC+healthy serum), the CD47 expression on CD14<jats:sup>+<\/jats:sup> monocyte stimulated with the PBC patients\u2019 serum (PBMC+PBC patients\u2019 serum) was increased (<jats:italic>P<\/jats:italic>&amp;lt;0.001); the CD47 expression on CD14<jats:sup>+<\/jats:sup> monocyte stimulated with IFN-\u03b1 (PBMC + IFN-\u03b1) increased gradually with the increased concentration of IFN-\u03b1 (<jats:italic>P<\/jats:italic>&amp;lt;0.05). However, there was no similar trend on CD14<jats:sup>+<\/jats:sup> monocyte stimulated with the TNF-\u03b1 (PBMC+TNF-\u03b1) (<jats:italic>P<\/jats:italic>&amp;gt;0.05). The levels of serum anti-CD47 antibody and IFN-\u03b1 in the PBC patients were higher than those in healthy subjects (<jats:italic>P<\/jats:italic>&amp;lt;0.05). The TNF-\u03b1 expression level in CD14<jats:sup>+<\/jats:sup> monocyte stimulated with the LPS (PBMC+LPS) or anti-CD47 antibody+LPS group (PBMC+LPS+anti-CD47 antibody) was significantly increased than that in the Control group (PBMC+isotype control antibody) (<jats:italic>P<\/jats:italic>&amp;lt;0.01 and <jats:italic>P<\/jats:italic>&amp;lt;0.001, respectively). The TNF-\u03b1 expression level in CD14<jats:sup>+<\/jats:sup> monocyte stimulated with the anti-CD47 antibody + LPS was higher than that with the LPS (<jats:italic>P<\/jats:italic>&amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The CD47 may be related to the pathogenesis of PBC by inflammatory response. The CD47\/SIRP\u03b1 signal were imbalanced in PBC patients. The presence of serum anti-CD47 antibodies in PBC patients provides a laboratory basis for clinical diagnosis and treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1256995","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:16:58Z","timestamp":1701667018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Regulation of CD47 expression on CD14+ monocytes by interferon-\u03b1 in PBC patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Xi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951x-245","article-title":"Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2020.0028","article-title":"Current understanding of primary biliary cholangitis","volume":"27","author":"Tanaka","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/mog.0000000000000703","article-title":"Primary biliary cholangitis: pathogenic mechanisms","volume":"37","author":"Prieto","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"B4","article-title":"Mechanisms of autoimmune liver disease","volume":"18","author":"Baier","year":"2014","journal-title":"Discovery Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/nu13031018","article-title":"The gut-liver axis in cholestatic liver diseases","volume":"13","author":"Blesl","year":"2021","journal-title":"Nutrients"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab369","article-title":"Loss of myeloid cell-specific SIRP\u03b1, but not CD47, attenuates inflammation and suppresses atherosclerosis","volume":"118","author":"Singla","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051151","article-title":"CD47 potentiates inflammatory response in systemic lupus erythematosus","volume":"10","author":"Park","year":"2021","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 Immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/614619","article-title":"CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg","year":"2013","journal-title":"ISRN Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020218","article-title":"Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors","volume":"12","author":"Dutta","year":"2023","journal-title":"Biol (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01903-2","article-title":"Blocking the CD47-SIRP\u03b1 interaction reverses the disease phenotype in a polycythemia vera mouse model","volume":"37","author":"Lysenko","year":"2023","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001408","article-title":"Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review","volume":"8","author":"Lecoultre","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.25.550566","article-title":"Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis","volume":"25","author":"Mackert","year":"2023","journal-title":"bioRxiv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.80725","article-title":"Anti-CD47 antibody enhances the efficacy of chemotherapy in patients with gastric cancer liver metastasis","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04292-8","article-title":"A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade","volume":"149","author":"Ozaniak","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680568","article-title":"CD47 deficiency ameliorates ocular autoimmune inflammation","volume":"12","author":"Okunuki","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v11.i6.239","article-title":"CD47 decline in pancreatic islet cells promotes macrophage-mediated phagocytosis in type I diabetes","volume":"11","author":"Zhang","year":"2020","journal-title":"World J Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100903","article-title":"CD47 promotes autoimmune valvular carditis by impairing macrophage efferocytosis and enhancing cytokine production","volume":"208","author":"Meier","year":"2022","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13258-023-01390-w","article-title":"Identification of ulcerative colitis-specific immune cell signatures from public single-cell RNA-seq data","volume":"45","author":"Kim","year":"2023","journal-title":"Genes Genomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152564","article-title":"Putting the brakes on phagocytosis: \"don't-eat-me\" signaling in physiology and disease","volume":"22","author":"Kelley","year":"2021","journal-title":"EMBO Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188771","article-title":"CD47: Beyond an immune checkpoint in cancer treatment","volume":"1877","author":"Bian","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: Current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2012.697470","article-title":"IFN-\u03b2, IFN-\u03b3, and TNF-\u03b1 decrease erythrophagocytosis by human monocytes independent of SIRP-\u03b1 or SHP-1 expression","volume":"34","author":"de Almeida","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700285","article-title":"Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis","volume":"85","author":"Takii","year":"2005","journal-title":"Lab Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29524","article-title":"The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity","volume":"67","author":"Bae","year":"2018","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101974","article-title":"Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice","volume":"209","author":"Han","year":"2012","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/path.4574","article-title":"CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production","volume":"237","author":"Shi","year":"2015","journal-title":"J Pathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102293","DOI":"10.1016\/j.jaut.2019.06.004","article-title":"Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis","volume":"103","author":"Li","year":"2019","journal-title":"J Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.23674","article-title":"Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator","volume":"58","author":"Oya","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1256995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:17:01Z","timestamp":1701667021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1256995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2023.1256995"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1256995","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"article-number":"1256995"}}